AZD 3241

Drug Profile

AZD 3241

Alternative Names: AZD-3241

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antiparkinsonians; Pyrimidinones; Small molecules
  • Mechanism of Action Peroxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple system atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple system atrophy; Parkinson's disease

Most Recent Events

  • 11 Jul 2017 Discontinued - Phase-II for Multiple system atrophy in France, Sweden, USA, Italy, United Kingdom, Finland and Austria (PO) (AstraZeneca pipeline, July 2017)
  • 01 Sep 2016 AstraZeneca completes a phase II trial in Multiple system atrophy in USA, Austria, Finland, France, Italy, Sweden and United Kingdom (NCT02388295)
  • 01 Apr 2015 AZD 3241 is still in phase-II development for Multiple system atrophy in United Kingdom, Italy, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top